Cerity Partners LLC Sells 85,679 Shares of Pfizer Inc. (NYSE:PFE)

Cerity Partners LLC trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,898,337 shares of the biopharmaceutical company's stock after selling 85,679 shares during the quarter. Cerity Partners LLC's holdings in Pfizer were worth $51,878,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of PFE. United Bank increased its stake in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after acquiring an additional 1,277 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Pfizer by 4.0% during the 3rd quarter. MML Investors Services LLC now owns 1,387,138 shares of the biopharmaceutical company's stock worth $40,144,000 after purchasing an additional 53,486 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Pfizer by 5.6% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 1,749,702 shares of the biopharmaceutical company's stock valued at $50,636,000 after buying an additional 92,596 shares during the last quarter. Groupama Asset Managment grew its stake in shares of Pfizer by 2.0% in the 3rd quarter. Groupama Asset Managment now owns 289,101 shares of the biopharmaceutical company's stock valued at $8,367,000 after buying an additional 5,604 shares in the last quarter. Finally, Geller Advisors LLC raised its position in Pfizer by 1.5% during the third quarter. Geller Advisors LLC now owns 29,913 shares of the biopharmaceutical company's stock valued at $866,000 after acquiring an additional 434 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.10 during mid-day trading on Friday, hitting $21.69. The company had a trading volume of 24,820,314 shares, compared to its average volume of 40,103,277. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market cap of $123.00 billion, a P/E ratio of 15.37, a PEG ratio of 0.64 and a beta of 0.67. The business's 50-day simple moving average is $25.33 and its 200-day simple moving average is $26.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on PFE shares. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lowered their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.07.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.